Reata Pharmaceuticals Inc. has received a $30m milestone payment from partner Kyowa Hakko Kirin Co. Ltd. following the Japanese firm’s initiation of a Phase III clinical trial program in Japan for bardoxolone (RTA 402) for the treatment of diabetic kidney disease.
The pivotal AYAME trial, which began enrolment in May, will assess the oral, once-daily Nrf2 activator in around 700 patients...







